Necrotizing Enterocolitis (NEC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Necrotizing Enterocolitis (NEC) Market Outlook

Thelansis’s “Necrotizing Enterocolitis (NEC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Necrotizing Enterocolitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Necrotizing Enterocolitis (NEC) Overview

Necrotizing enterocolitis (NEC) primarily afflicts preterm infants, reflecting the remarkable advances in neonatology that have enabled the survival of babies born at lower gestational ages, a feat unimaginable a few decades ago. It stands as one of the most devastating maladies encountered in neonatal intensive care, characterized by staggering rates of morbidity, mortality, and financial burden. Long-term consequences include intestinal strictures, adhesions, cholestasis, short bowel syndrome, failure to thrive, and neurodevelopmental delays. Regrettably, efforts to treat or prevent NEC have seen limited success. The underdeveloped physiological functions of preterm infants, including immature barrier function, circulatory regulation, motility, digestion, absorption, and immune defenses, contribute to the vulnerability to NEC. Furthermore, the delicate balance between inflammatory and tolerogenic immune responses must still be developed. Classic NEC often manifests with excessive inflammatory reactions, evidenced by elevated serum levels of cytokines and chemokines, notably IL-8. Potential biomarkers for NEC include claudin 3, an integral component of tight junctions, an intestinal fatty acid-binding protein produced by epithelial cells, and fecal calprotectin, a product of inflammatory cells. Despite ongoing research, there is currently no FDA-approved treatment for NEC.

• Necrotizing enterocolitis (NEC) affects a significant proportion of low-birth-weight infants, with up to 5% incidence among this population. It is particularly prevalent in those weighing less than 1,500 grams at birth. Additionally, NEC accounts for approximately 7 to 14% of cases among full-term infants.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: